Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

Class:IdLiteratureReference:9702799
_displayNameThe Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
_timestamp2020-10-02 10:45:38
author[Person:9702781] Broessner, Gregor
[Person:9702831] Reuter, Uwe
[Person:9702809] Bonner, Jo H
[Person:9702355] Dodick, David W
[Person:9702826] Hallström, Yngve
[Person:9702798] Picard, Hernan
[Person:5621527] Zhang, Feng
[Person:9702834] Lenz, Robert A
[Person:9702802] Klatt, Jan
[Person:9702835] Mikol, Daniel D
created[InstanceEdit:9702847] Jassal, Bijay, 2020-10-02
journalHeadache
pages2026-2040
pubMedIdentifier32851644
titleThe Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
volume60
year2020
(literatureReference)[Reaction:9702818] CALCR binds erenumab [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response (9702799)